Unicycive Therapeutics Inc (NASDAQ:UNCY)’s traded shares stood at 1.12 million during the last session, with the company’s beta value hitting 2.32. At the close of trading, the stock’s price was $0.67, to imply an increase of 1.35% or $0.01 in intraday trading. The UNCY share’s 52-week high remains $1.82, putting it -171.64% down since that peak but still an impressive 70.15% since price per share fell to its 52-week low of $0.20. The company has a valuation of $69.54M, with an average of 1.44 million shares in intraday trading volume over the past 10 days and average of 1.58 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Unicycive Therapeutics Inc (UNCY), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give UNCY a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.07.
Unicycive Therapeutics Inc (NASDAQ:UNCY) trade information
After registering a 1.35% upside in the last session, Unicycive Therapeutics Inc (UNCY) has traded red over the past five days. The 5-day price performance for the stock is -13.86%, and -9.46% over 30 days. With these gigs, the year-to-date price performance is -15.64%. Short interest in Unicycive Therapeutics Inc (NASDAQ:UNCY) saw shorts transact 1.05 million shares and set a 0.74 days time to cover.
Unicycive Therapeutics Inc (UNCY) estimates and forecasts
Looking at statistics comparing Unicycive Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Unicycive Therapeutics Inc (UNCY) shares are 41.95% up over the last 6 months, with its year-to-date growth rate lower than industry average at 5.00% against 16.30%. The rating firms project that company’s revenue will shrink -100.00% compared to the previous financial year.
UNCY Dividends
Unicycive Therapeutics Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Unicycive Therapeutics Inc (NASDAQ:UNCY)’s Major holders
Unicycive Therapeutics Inc insiders hold 6.73% of total outstanding shares, with institutional holders owning 38.24% of the shares at 41.00% float percentage. In total, 38.24% institutions holds shares in the company, led by VIVO CAPITAL, LLC. As of 2024-06-30, the company held over 3.47 million shares (or 9.9395% of shares), all amounting to roughly $1.74 million.
The next major institution holding the largest number of shares is LOGOS GLOBAL MANAGEMENT LP with 3.47 million shares, or about 9.9389% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $1.74 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Unicycive Therapeutics Inc (UNCY) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 765.0 shares. This is just over 0.74% of the total shares, with a market valuation of $0.51 million. Data from the same date shows that the other fund manager holds a little less at 373.22, or 0.36% of the shares, all valued at about 0.25 million.
